Posted by Michael Wonder on 11 Sep 2020
Junshi Biosciences receives FDA breakthrough therapy designation for toripalimab for the treatment of nasopharyngeal carcinoma
10 September 2020 - Junshi Biosciences announced today that the US FDA has recently granted breakthrough therapy designation to toripalimab for the treatment of nasopharyngeal carcinoma.
Toripalimab is the first anti-PD-1 antibody from China to receive the breakthrough therapy designation, which is another important regulatory milestone for toripalimab after FDA granted orphan drug designation for this indication in May 2020.
